Tumor necrosis factor-α: A possible priming agent for the polymorphonuclear leukocyte-reduced nicotinamide-adenine dinucleotide phosphate oxidase in hypertension

Hypertension

Volumn 55, Issue 2, 2010, Pages 353-362

  Mazor, Rafi ^a,b   Itzhaki, Osnat ^a   Sela, Shifra ^a,b   Yagil, Yoram ^c   Cohen Mazor, Meital ^a,b   Yagil, Chana ^c   Kristal, Batya ^a,b  

^a WESTERN GALILEE HOSPITAL   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c Laboratory for Molecular Medicine   (Israel)

Author keywords

Hypertension; Inflammation; NADPH oxidase; Oxidative stress; TNF ; TNF receptor

Indexed keywords

APOCYNIN; FIBRINOGEN; GAMMA INTERFERON; INTERLEUKIN 6; MALONALDEHYDE; PROTEIN P55; PROTEIN P75; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FLOW CYTOMETRY; HYPERTENSION; NEUTROPHIL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SALT INTAKE; WESTERN BLOTTING;

ACETOPHENONES; ANALYSIS OF VARIANCE; ANIMALS; BLOOD PRESSURE DETERMINATION; CYTOKINES; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; HYPERTENSION; IMMUNOHISTOCHEMISTRY; MALONDIALDEHYDE; NADPH OXIDASE; NEUTROPHILS; OXIDATIVE STRESS; PROBABILITY; RANDOM ALLOCATION; RATS; RATS, INBRED SHR; SODIUM CHLORIDE, DIETARY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 74949130288     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.109.144154     Document Type: Article

References (47)

1. Bayorh MA, Ganafa AA, Socci RR, Silvestrov N, Abukhalaf IK. The role of oxidative stress in salt-induced hypertension. Am J Hypertens. 2004; 17:31-36.
2. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contribution to alterations of vasomotor tone. J Clin Invest. 1996;15:1916-1923.
3. Meng S, Cason GW, Gannon AW, Racusen LC, Manning RD Jr. Oxi-dative stress in Dahl salt-sensitive hypertension. Hypertension. 2003;41: 1346-1352.
4. Wassmann S, Laufs U, Stamenkovic D, Linz W, Stasch JP, Ahlbory K, Rosen R, Bohm M, Nickenig G. Raloxifene improves endothelial dysfunction in hypertension by reduced oxidative stress and enhanced nitric oxide production. Circulation. 2002;105:2083-2091.
5. El Midaoui A, de Champlain J. Prevention of hypertension, insulin resistance, and oxidative stress by alpha-lipoic acid. Hypertension. 2002; 39:303-307.
6. Vaziri ND, Rodriguez-Iturbe B. Mechanisms of disease: oxidative stress and inflammation in the pathogenesis of hypertension. Nat Clin Pract Nephrol. 2006;2:582-593.
7. Kristal B, Shurtz-Swirski R, Chezar J, Manaster J, Levy R, Shapiro G, Weissman I, Shasha SM, Sela S. Participation of peripheral poly-morphonuclear leukocytes in the oxidative stress and inflammation in patients with essential hypertension. Am J Hypertens. 1998;11:921-928.
8. Shurtz-Swirski R, Sela S, Herskovits AT, Shasha SM, Shapiro G, Nasser L, Kristal B. Involvement of peripheral polymorphonuclear leukocytes in oxidative stress and inflammation in type 2 diabetic patients. Diabetes Care. 2001;24:104-110.
9. Sela S, Shurtz-Swirski R, Cohen-Mazor M, Mazor R, Chezar J, Shapiro G, Hassan K, Shkolnik G, Geron R, Kristal B. Primed peripheral poly-morphonuclear leukocyte: a culprit underlying chronic low-grade inflammation and systemic oxidative stress in chronic kidney disease. J Am Soc Nephrol. 2005;16:2431-2438.
10. Swain Sd. Neutrophil priming in host defense: role of oxidants as priming agents. Antioxid Redox Signal. 2002;4:69-83.
11. Babior BM. The respiratory burst oxidase. Adv Enzymol Relat Areas Mol Biol. 1992;65:49-95.
12. Sela S, Mazor R, Amsalam M, Yagil C, Yagil Y, Kristal B. Primed polymorphonuclear leukocytes, oxidative stress, and inflammation antecede hypertension in the Sabra rat. Hypertension. 2004;44:764-769.
13. Mazor R, Kristal B, Cohen-Mazor M, Yagil C, Yagil Y, Sela S. The polymorphonuclear leukocyte contributes to the development of hypertension in the Sabra rat. J Hypertens. 2007;25:2249-2256.
14. Park YM, Park MY, Suh YL, Park JB. NAD(P)H oxidase inhibitor prevents blood pressure elevation and cardiovascular hypertrophy in aldosterone-infused rats. Biochem Biophys Res Commun. 2004;313: 812-817.
15. Beswick RA, Dorrance AM, Leite R, Webb RC. NADH/NADPH oxidase and enhanced superoxide production in the mineralocorticoid hypertensive rat. Hypertension. 2001;38:1107-1111.
16. Keidar S, Kaplan M, Pavlotzky E, Coleman R, Hayek T, Hamoud S, Aviram M. Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin- converting enzyme and the receptors for angiotensin II and aldosterone. Circulation. 2004;109:2213-2220.
17. Dewas C, Dang PM, Gougerot-Pocidalo MA, El-Benna J. TNF-alpha induces phosphorylation of p47(phox) in human neutrophils: partial phos-phorylation of p47phox is a common event of priming of human neu-trophils by TNF-alpha and granulocyte-macrophage colony-stimulating factor. J Immunol. 2003;15:4392-4398.
18. Suematsu M, Suzuki H, Delano FA, Schmid-Schönbein GW. The inflammatory aspect of the microcirculation in hypertension: oxidative stress, leukocytes/endothelial interaction, apoptosis. Microcirculation. 2002;9: 259-276.
19. Savoia C, Schiffrin EL. Inflammation in hypertension. Curr Opin Nephrol Hypertens. 2006;15:152-158.
20. Shao J, Nangaku M, Miyata T, Inagi R, Yamada K, Kurokawa K, Fujita T. Imbalance of T-cell subsets in angiotensin II-infused hypertensive rats with kidney injury. Hypertension. 2003;42:31-38.
21. Van Heuven-Nolsen D, De Kimpe SJ, Muis T, van Ark I, Savelkoul H, Beems RB, van Oosterhout AJ, Nijkamp FP. Opposite role of interferon-gamma and interleukin-4 on the regulation of blood pressure in mice. Biochem Biophys Res Commun. 1999;254:816-820.
22. Ishimitsu T, Uehara Y, Numabe A, Tsukada H, Ogawa Y, Iwai J, Ikeda T, Matsuoka H, Sugimoto T, Yagi S. Interferon gamma attenuates hypertensive renal injury in salt-sensitive Dahl rats. Hypertension. 1992;19: 804-808.
23. Ikeda Y, Takeuchi K, Kato T, Taniyama Y, Sato K, Takahashi N, Sugawara A, Ito S. Transcriptional suppression of rat angiotensin AT1a receptor gene expression by interferon-gamma in vascular smooth muscle cells. Biochem Biophys Res Commun. 1999;262:494-498.
24. Sanz-Rosa D, Oubioa MP, Cediel E, de Las Heras N, Vegazo O, Jiménez J, Lahera V, Cachofeiro V. Effect of AT1 receptor antagonism on vascular and circulating inflammatory mediators in SHR: role of NF-kappaB/IkappaB system. Am J Physiol Heart Circ Physiol. 2005;288: H111-H115.
25. Lee DL, Sturgis LC, Labazi H, Osborne JB, Fleming C, Pollock JS, Manhiani M, Imig JD, Brands MW. Angiotensin II hypertension is attenuated in interleukin-6 knockout mice. Am J Physiol Heart Circ Physiol. 2006;290:H935-H940.
26. Gu JW, Tian N, Shparago M, Tan W, Bailey AP, Manning RD. Renal NF-kappaB activation and TNF-alpha upregulation correlate with salt-sensitive hypertension in Dahl salt-sensitive rats. Am J Physiol Regul Integr Comp Physiol. 2006;291:R1817-R1824.
27. Higashi Y, Sasaki S, Kurisu S, Yoshimizu A, Sasaki N, Matsuura H, Kajiyama G, Oshima T. Regular aerobic exercise augments endothelium-dependent vascular relaxation in normotensive as well as hypertensive subjects: role of endothelium-derived nitric oxide. Circulation. 1999;100: 1194-1202.
28. Brasier AR, Li J, Wimbish KA. Tumor necrosis factor activates angio-tensinogen gene expression by the Rel Atransactivator. Hypertension. 1996;27:1009-1017.
29. Dörffel Y, Lätsch C, Stuhlmüller B, Schreiber S, Scholze S, Burmester GR, Scholze J. Preactivated peripheral blood monocytes in patients with essential hypertension. Hypertension. 1999;34:113-117.
30. El Benna J, Hayem G, Dang P, Fay M, Chollet-Martin S, Elbim C, Meyer O, Gourgeot-Pocidalo MA. NADPH oxidase priming and p47phox phosphorylation in neutrophils from synovial fluid of patients with rheumatoid arthritis and spondyloarthropathy. Inflammation. 2002;26: 273-278.
31. Nathan CF. Neutrophil activation on biological surfaces. Massive secretion of hydrogen peroxide in response to products of macrophages and lymphocytes. J Clin Invest. 1987;80:1550-1560.
32. Richter J, Andersson T, Ollson I. Effect of tumor necrosis factor and granulocyte/macrophage colony-stimulating factor of neutrophil degran-ulation. J Immunol. 1989;142:3199-3205.
33. Nguyen HX, O'barr TJ, Anderson AJ. Polymorphonuclear leukocytes promote neurotoxocity through release of matrix metalloproteinases, reactive oxygen species and TNFa. J Neurochem. 2007;102:900-912.
34. Miesel R, Hartung R, Kroeger H. Priming of NADPH oxidase by tumor necrosis factor alpha with inflammatory and autoimmune rheumatic diseases. Inflammation. 1996;20:427-438.
35. Shahid M, Francis J, Majid DS. Tumor necrosis factor-alpha induces renal vasoconstriction as well as natriuresis in mice. Am J Physiol Renal Physiol. 2008;295:F1836-F1844.
36. Sriramula S, Haque M, Majid DS, Francis J. Involvement of tumor necrosis factor-alpha in angiotensin II-mediated effects on salt appetite, hypertension, and cardiac hypertrophy. Hypertension. 2008;51: 1345-1351.
37. Vandenabeele P, Declercq W, Beyaert R, Fiers W. Two tumour necrosis factor receptors: structure and function. Trends Cell Biol. 1995;5: 392-399.
38. Welborn MB III, Van Zee K, Edwards PD, Pruitt JH, Kaibara A, Vauthey JN, Rogy M, Castleman WL, Lowry SF, Kenney JS, Stüber D, Ettlin U, Wipf B, Loetscher H, Copeland EM III, Lesslauer W, Moldawer LL. A human tumor necrosis factor p75 receptor agonist stimulates in vitro T cell proliferation but does not produce inflammation or shock in the baboon. J Exp Med. 1996;1:165-171.
39. MacEwan DJ. TNF receptor subtype signalling: differences and cellular consequences. Cell Signal. 2002;14:477-479.
40. Barbara JA, Smith WB, Gamble JR, Van Ostade X, Vandenabeele P, Tavernier J, Fiers W, Vadas MA, Lopez AF. Dissociation of TNFa cytotoxic and proinflammatory activities by p55 receptor and p75 receptor-selective TNFa mutans. EMBO J. 1994;13:843-850.
41. Higuchi M, Aggarwal BB. Tumor necrosis factor infuces internalization of the p60 receptor and shedding of the p80 receptor. J Immunol. 1994; 152:3550-3558.
42. Iliescu R, Cucchiarelli VE, Yanes LL, Iles JW, Reckelhoff JF. Impact of androgen-induced oxidative stress on hypertension in male SHR. Am J Physiol Regul Integr Comp Physiol. 2007;292:R731-R735.
43. Hu L. Apocynin but not L-arginine prevents and reverses dexametha-sone-induced hypertension in the rat. Am J Hypertens. 2006;19:413-418.
44. Hougee S, Hartog A, Sanders A, Graus YM, Hoijer MA, Garssen J, van den Berg WB, van Beuningen HM, Smit HF. Oral administration of the NADPH-oxidase inhibitor apocynin partially restores diminished cartilage proteoglycan synthesis and reduces inflammation in mice. Eur J Pharmacol. 2006;15:264-269.
45. Fujii S, Zhang L, Igarashi J, Kosaka H. L-arginine reverses p47phox and gp91phox expression induced by high salt in Dahl rats. Hypertension. 2003;42:1014-1020.
46. Williams HC, Griendling KK. NADPH oxidase inhibitors: new antihy-pertensive agents? J Cardiovasc Pharmacol. 2007;50:9-16.
47. Rees D, Ben-Ishay D, Moncada S. Nitric oxide and the regulation of blood pressure in the hypertension-prone and hypertension-resistant Sabra rat. Hypertension. 1996;28:367-371.